PLC
ACRS icon

Peapod Lane Capital’s Aclaris Therapeutics ACRS Stock Holding History

Peapod Lane Capital’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-404,452
Closed -$1M – 62
2024
Q4 		$1M Buy
+404,452
New +$1.01M 0.99% 42

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Peapod Lane Capital's ACRS Position: Q1 2025 in Review

Peapod Lane Capital sold out of Aclaris Therapeutics (ACRS) in Q1 2025, closing a stake of 404,452 shares — an estimated $1M sold.

Peapod Lane Capital first reported a position in ACRS in Q4 2024 and held it in 1 quarter. The position peaked at $1M in Q4 2024. 109 funds tracked by Wall St. Rank hold ACRS as of Q1 2025.

  • Peapod Lane Capital reported no remaining Aclaris Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Peapod Lane Capital sold 404,452 Aclaris Therapeutics shares in Q1 2025, an estimated $1M.
  • Peapod Lane Capital first reported a position in Aclaris Therapeutics in Q4 2024 and held it in 1 quarter.
  • Peapod Lane Capital's Aclaris Therapeutics position peaked at $1M in Q4 2024.
  • 109 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2025.

Based on Peapod Lane Capital's 13F filing for Q1 2025, filed 30 Apr 2025.